First-line systemic treatment with gefitinib in stage IV non-small cell lung cancer

Oncology Reports

Volumn 14, Issue 6, 2005, Pages 1539-1542

  Lange, Tobias ^a   Müller Tidow, Carsten ^a   Serve, Hubert ^a   Hoffknecht, Petra ^a   Berdel, Wolfgang E ^a   Thomas, Michael ^a,b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Epithelial growth factor receptor; Erlotinib; Firstline treatment; Gefitinib; Non small cell lung cancer; Targeted therapy; Tyrosine kinase

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; QUINAZOLINE DERIVATIVE;

ADENOCARCINOMA; ARTICLE; BONE TUMOR; CANCER STAGING; CASE REPORT; DRUG ANTAGONISM; FEMALE; GENE DELETION; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METASTASIS; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PATHOLOGY; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE DELETION; TREATMENT OUTCOME;

EID: 33644698120     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.14.6.1539     Document Type: Article

References (18)

1. Jemal A, Tiwari RC, Murray T, et al: Cancer statistics, 2004. CA Cancer J Clin 54: 8-29, 2004. (Pubitemid 38443417)
2. Shepherd FA, Pereira JR., Ciuleanu TE, et al for the National Cancer Institute of Canada Clinical Trials Group: Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353: 123-132, 2005.
3. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290: 2149-2158, 2003. (Pubitemid 37432975)
4. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol 21: 2237-2246, 2003. (Pubitemid 46621858)
5. Miller VA, Kris MG, Shah N, et al: Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small cell lung cancer. J Clin Oncol 22: 1103-1109, 2004. (Pubitemid 41095044)
6. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004. (Pubitemid 38637993)
7. Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004. (Pubitemid 38720929)
8. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306-13311, 2004. (Pubitemid 39209661)
9. Marchetti A, Martella C, Felicioni L, et al: EGFR mutations in non-small cell lung cancer: Analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23: 857-865, 2005. (Pubitemid 46224186)
10. Müller-Tidow C, Diederichs S, Bulk E, et al: Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer. Cancer Res 65: 1778-1782, 2005. (Pubitemid 40478604)
11. Meert AP, Martin B, Delmotte P, et al: The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J 20: 975-981, 2002. (Pubitemid 35175137)
12. Argiris A and Mittal N: Gefitinib as first-line, compassionate use therapy in patients with advanced non-small cell lung cancer. Lung Cancer 43: 317-322, 2004. (Pubitemid 38224152)
13. Kommareddy A, Coplin MA, Gao F, et al: Single agent gefitinib as first-line therapy in patients with advanced non-small cell lung caner: Washington University experience. Lung Cancer 45: 221-225, 2004. (Pubitemid 38891485)
14. Cohen MH, Williams GA, Sridhara R, et al: United States Food and Drug Administration drug approval summary: Gefitinib (ZD 1839; Iressa) tablets. Clin Cancer Res 10: 1212-1218, 2004. (Pubitemid 38365209)
15. Gorre ME, Mohammed E, Ellwood K, et al: Clinical resistance to STI-571 cancer therapy caused by bcr-abl gene mutation or amplification. Science 293: 876-880, 2001. (Pubitemid 32743979)
16. Kobayashi S, Boggon TJ, Dayaram T, et al: EGFR mutation and resistance of non-small cell lung cancer to gefitinib. N Engl J Med 352: 786-792, 2005. (Pubitemid 40271173)
17. Shah NP, Tran C, Lee FY, et al: Overriding imatinib resistance with a novel abl kinase inhibitor. Science 305: 319-321, 2004.
18. Pérez-Soler R, Chachoua A, Hammond LA, et al: Determinants of tumor response and survival with erlotinib in patients with non-small cell lung cancer. J Clin Oncol 22: 3238-3247, 2004. (Pubitemid 41103678)